Shares if ibogaine-related biotech companies are trading higher after President Trump said in a social media post that the University of Miami shared its 1994 ibogaine Investigational New Drug Application with the government, which will help accelerate development as a medical treatment in the U.S.

This headline signals a potentially significant acceleration in ibogaine's development as a medical treatment in the U.S., driven by political endorsement and access to historical IND data. This could lead to increased investor interest and valuation for companies actively pursuing ibogaine-based therapies.

The President's social media post, highlighting the sharing of a 1994 IND application, acts as a powerful catalyst for the ibogaine sector. This suggests a potential fast-tracking of regulatory processes, reducing development timelines and costs for companies in this space. Key risks include the actual efficacy and safety data from the IND, the FDA's ultimate decision, and the long-term commercial viability. The biotechnology sector, specifically companies focused on psychedelic or addiction treatments, will be most affected. Traders should monitor regulatory updates and company announcements closely, as this news could lead to sustained upward momentum for relevant stocks, but also potential volatility if regulatory hurdles remain.